Participants 24 123 4
phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma
Participants 170 385 8
survival of patients randomised in a previously reported multicentre phase III study of topotecan versus paclitaxel in patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen
Participants 408 485 7
Patients with bidimensionally measurable disease were randomised to topotecan
Participants 946 997 8
A total of 226 patients were evaluable for response
Participants 1817 1889 4
this group of patients receiving topotecan at relapse of ovarian cancer.
